I don't know what is meant by "modified" but I did find this:
Surg Obes Relat Dis. 2014 Sep-Oct;10(5):795-9. doi: 10.1016/j.soard.2014.01.013. Epub 2014 Jan 29.
Gastric bypass surgery as treatment of recalcitrant gastroparesis.
Papasavas PK1,
Ng JS2,
Stone AM2,
Ajayi OA3,
Muddasani KP4,
Tishler DS2.
Author information
Abstract
BACKGROUND:
Few treatments for idiopathic and diabetic gastroparesis exist beyond symptom management, and no study has described gastric surgery for gastroparesis in obese and morbidly obese patients. The objective of this study was to describe treatment of recalcitrant gastroparesis in obese adults with Roux-en-Y gastric bypass (RYGB) surgery.
METHODS:
A retrospective review was conducted of adult patients who underwent laparoscopic RYGB. Clinical data pre- and postsurgery and at a follow-up of up to 2 years were reviewed. Total symptom scores for gastroparetic symptom severity and frequency were compared presurgery and at follow-up using paired t tests.
RESULTS:
Seven obese and morbidly obese patients (body mass index [BMI] = 39.5, range = 33-54; 6 women) with idiopathic or diabeticgastroparesis reported marked symptom improvement, and total symptom scores significantly decreased after RYGB. All 4 patients who were taking prokinetics preoperatively no longer required their medication after surgery. Three patients required prolonged treatment with antinausea medications in the postoperative period. Mean BMI change was 9.1 units and mean percent excess weight lost was 71.6 lbs. No perioperative complications were experienced. Two required readmissions due to various concerns (dysphagia, nausea, anastomotic ulcer).
CONCLUSIONS:
In our cohort, no patients required the use of prokinetics after surgery and everyone experienced significant improvement in symptoms. Importantly, we found that RYGB is a safe surgical treatment for gastroparesis in obese patients. Our results indicate that gastroparesis, primarily believed to result in being underweight, can present in morbid obesity and can be markedly improved with RYGB.
Copyright © 2014 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved.
And this:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3722580/pdf/nihms489116.pdf
Am J Gastroenterol. 2013 Jan;108(1):18-37; quiz 38. doi: 10.1038/ajg.2012.373. Epub 2012 Nov 13.
Clinical guideline: management of gastroparesis.
Camilleri M1,
Parkman HP,
Shafi MA,
Abell TL,
Gerson L;
American College of Gastroenterology.
Author information
Abstract
This guideline presents recommendations for the evaluation and management of patients with gastroparesis. Gastroparesis is identified in clinical practice through the recognition of the clinical symptoms and documentation of delayed gastric emptying. Symptoms from gastroparesis include nausea, vomiting, early satiety, postprandial fullness, bloating, and upper abdominal pain. Management of gastroparesis should include assessment and correction of nutritional state, relief of symptoms, improvement of gastric emptying and, in diabetics, glycemic control. Patient nutritional state should be managed by oral dietary modifications. If oral intake is not adequate, then enteral nutrition via jejunostomy tube needs to be considered. Parenteral nutrition is rarely required when hydration and nutritional state cannot be maintained. Medical treatment entails use of prokinetic and antiemetic therapies. Current approved treatment options, including metoclopramide and gastric electrical stimulation (GES, approved on a humanitarian device exemption), do not adequately address clinical need. Antiemetics have not been specifically tested in gastroparesis, but they may relieve nausea and vomiting. Other medications aimed at symptom relief include unapproved medications or off-label indications, and include domperidone, erythromycin (primarily over a short term), and centrally acting antidepressants used as symptom modulators. GES may relieve symptoms, including weekly vomiting frequency, and the need for nutritional supplementation, based on open-label studies. Second-line approaches include venting gastrostomy or feeding jejunostomy; intrapyloric botulinum toxin injection was not effective in randomized controlled trials. Most of these treatments are based on open-label treatment trials and small numbers. Partial gastrectomy and pyloroplasty should be used rarely, only in carefully selected patients. Attention should be given to the development of new effective therapies for symptomatic control.
Comment in
SURGICAL TREATMENTS: VENTING GASTROSTOMY, GASTROJEUNOSTOMY, PYLOROPLASTY, AND GASTRECTOMY
Summary of Evidence
In patients with significant upper GI motility disorders, surgically placed venting gastrostomy, with or without a venting enterostomy, reduced hospitalization rate by a factor of 5 during the year after placement (163,164). Results of endoscopic venting (percutaneous endoscopic gastrostomy and direct percutaneous endoscopic jejunostomy) on nutritional outcomes and gastroparesis symptoms have not been formally studied and remain unclear. In an open-label study, patients experienced marked symptomatic improvement, weight was maintained, and total symptom score was reduced up to 3 years post venting gastrostomy (165). It is assumed that the same beneficial outcome occurs with percutaneous endoscopic gastrostomy, though this is not proven.
Several types of surgical interventions have been tried for treatment of gastroparesis: gastrojejunostomy, pyloromyotomy, and completion or subtotal gastrectomy. A recent study reported on a series of 28 patients with gastroparesis in whom pyloroplasty resulted in symptom improvement, with significant improvement in gastric emptying and reduction in the need for prokinetic therapy when followed at 3 months post surgery (166). It is unclear whether the efficacy of pyloroplasty depends on the residual antral motor function; thus, in the few diabetics included in the series, there was no significant improvement in gastric emptying (166), and further studies with longer follow-up are needed to determine overall efficacy and optimal candidates for pyloroplasty to treat gastroparesis. Completion or subtotal gastrectomy was applied most often for gastroparesis that followed gastric surgery for peptic ulcer disease (167,168); experience from tertiary referral centers suggests that, in carefully selected patients, major gastric surgery can relieve distressing vomiting from severe gastroparesis and improve quality of life (169,170) in seriously affected patients where risk of subsequent renal failure is high and where life expectancy is poor. The risk of malnutrition and weight loss following gastrectomy has to be weighed relative to the symptom relief. The use of completion or subtotal gastrectomy in patients with intact gastroparetic stomachs has not been favorable. Pyloroplasty may relieve symptoms in gastroparesis and is often combined with operative jejunal tube placement to support nutrition (166,171). Subtotal gastrectomy with Roux-Y reconstruction may be needed for gastric atony secondary to PSG (167). In patients undergoing surgical treatment for gastroparesis, a full-thickness gastric biopsy may be helpful to assess the pathologic basis associated with the patient’s gastroparesis (172–175).